Is Thoratech Getting Enough Premium in its Buyout?
Both companies announced the approval for a definitive agreement in which St. Jude Medical will acquire Thoratec in a cash transaction valued at roughly $3.4 billion.
Both companies announced the approval for a definitive agreement in which St. Jude Medical will acquire Thoratec in a cash transaction valued at roughly $3.4 billion.
Some investors may raise an eye as Merrill Lynch adds Facebook at prices near a 52-week high. The bottom line is the company is basically in a world with no competition.
Caterpillar has released its monthly retail sales report, just one day ahead of the company’s scheduled second-quarter earnings report.
Coca-Cola reported better-than-expected second-quarter financial results Wednesday before the markets opened.
EMC reported mixed second-quarter 2015 results before markets opened Wednesday morning.
This is the perfect time for aggressive growth investors to look to value stocks for a rotation, and a new report from Jefferies highlights five top picks for this week.
Boeing reported better-than-expected second-quarter 2015 results before markets opened Wednesday morning.
Wednesday's top analyst upgrades, downgrades and initiations include Apple, Exxon Mobil, LifeLock, Microsoft, PayPal and Chipotle Mexican Grill.
A new report from Cowen says that in the next two years the U.S. natural gas market could turn from a domestic to an international market.
The latest Mortgage Bankers Association's report on mortgage applications noted a week-over-week increase of a scant 0.1%.
In a move that has been expected for at least two weeks, FedEx announced late Tuesday that it has placed a firm order for 50 additional Boeing 767-300F freighters.
The next iPhone will be the most critical contributor to the recovery of Apple's shares, which were beaten down after earnings disappointed Wall Street.
In another example of how "Big Brother" has rapidly moved into the world of tech, the new Google Maps product can tell you where you have been.
UnitedHealth Group has confirmed what investors were expecting with the sale of billions of dollars in debt.
It appears that Exelixis assumed now would be the best time to dilute following its most recent successful in clinical trial and get more bang for its buck.